Regulation of growth of prostate cancer cells selected in the presence of interleukin‐6 by the anti‐interleukin‐6 antibody CNTO 328

No abstract is available for this paper.

• Publication year

  2006

• Venue

  The Prostate

• Publication date

  2006-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/pros.20492PMID 16998813
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice.

  2006cited by this paper
• Combination Therapy with Interleukin-6 Receptor Superantagonist Sant7 and Dexamethasone Induces Antitumor Effects in a Novel SCID-hu In vivo Model of Human Multiple Myeloma

  2005cited by this paper
• Interleukin‐6 and oncostatin M stimulation of proliferation of prostate cancer 22Rv1 cells through the signaling pathways of p38 mitogen‐activated protein kinase and phosphatidylinositol 3‐kinase

  2005cited by this paper
• Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer: Direct STAT3 inhibition induces apoptosis in prostate cancer lines.

  2004cited by this paper
• Comparison of gene expression in HCT116 treatment derivatives generated by two different 5-fluorouracil exposure protocols

  2004cited by this paper
• Interleukin-6-dependent gene expression profiles in multiple myeloma INA-6 cells reveal a Bcl-2 family-independent survival pathway closely associated with Stat3 activation.

  2004cited by this paper
• CNTO 328, a monoclonal antibody to IL‐6, inhibits human tumor‐induced cachexia in nude mice

  2004cited by this paper
• The role of the inhibitors of interleukin-6 signal transduction SHP2 and SOCS3 for desensitization of interleukin-6 signalling.

  2004cited by this paper
• An autocrine loop for vascular endothelial growth factor is established in prostate cancer cells generated after prolonged treatment with interleukin 6.

  2004cited by this paper
• Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells.

  2003cited by this paper
• Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway.

  2003cited by this paper
• LuCaP 35: A new model of prostate cancer progression to androgen independence

  2003cited by this paper
• Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence.

  2003cited by this paper
• Effects of IL-6 Variants in Multiple Myeloma: Growth Inhibition and Induction of Apoptosis in Primary Cells

  2002cited by this paper
• Interleukin-6 is an autocrine growth factor in human prostate cancer.

  2001cited by this paper
• Anti‐interleukin‐6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice

  2001cited by this paper
• A NOVEL AND RAPID PREDICTION ASSAY FOR THE EFFECTIVENESS OF IL‐6 RECEPTOR SPECIFIC ANTISENSE OLIGONUCLEOTIDES BY PROLIFERATION INHIBITION OF AN INTERLEUKIN‐6 DEPENDENT CELL LINE

  2001cited by this paper
• Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype.

  2001cited by this paper
• STAT3 mediates IL‐6‐induced growth inhibition in the human prostate cancer cell line LNCaP

  2000cited by this paper
• Interleukin-6 activates phosphatidylinositol-3 kinase, which inhibits apoptosis in human prostate cancer cell lines.

  2000cited by this paper
• Characterization of the role of IL‐6 in the progression of prostate cancer

  1999cited by this paper
• Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor.

  1998cited by this paper
• Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro.

  1997cited by this paper
• Induction of "tissue" transglutaminase in HIV pathogenesis: evidence for high rate of apoptosis of CD4+ T lymphocytes and accessory cells in lymphoid tissues.

  1996cited by this paper
• Stromal cells from human benign prostate hyperplasia produce a growth‐inhibitory factor for LNCaP prostate cancer cells, identified as interleukin‐6

  1996cited by this paper
• Interleukin-6: a candidate mediator of human prostate cancer morbidity.

  1995cited by this paper
• Growth of an androgen‐sensitive human prostate cancer cell line, LNCaP, in nude mice

  1993cited by this paper
• A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

  1976cited by this paper
• Letter: Cancer xenografts in nude mice.

  1976cited by this paper

• Paracrine Factors Released from Tonsil-Derived Mesenchymal Stem Cells Inhibit Proliferation of Hematological Cancer Cells Under Hyperthermia in Co-culture Model

  2023cites this paper
• miR-26a-5p restoration via EZH2 silencing blocks the IL-6/STAT3 axis to repress the growth of prostate cancer

  2023cites this paper
• Ten interleukins and risk of prostate cancer

  2023cites this paper
• Tonsil-Derived Mesenchymal Stem Cells Inhibit the Proliferation of Hematological Cancer Cells through Downregulation of IL-6 Gene Expression under Hyperthermia

  2021cites this paper
• A Systematic Review on Security and Privacy Issues in Mobile Devices and Systems

  2020cites this paper
• Resistance to anti-hormonal therapy in prostate cancer

  2019cites this paper
• The STAT3 Inhibitor Galiellalactone Reduces IL6-Mediated AR Activity in Benign and Malignant Prostate Models

  2018cites this paper
• A role for paracrine interleukin‐6 signaling in the tumor microenvironment in prostate tumor growth

  2018cites this paper
• Interleukin-6 and prostate cancer: Current developments and unsolved questions.

  2017cites this paper
• STAT3 in Prostate Cancer: Whom Should We Treat and When?

  2017cites this paper
• Siltuximab: a new option for the management of Castleman's disease.

  2015cites this paper
• Inflammation and prostate cancer: the role of interleukin 6 (IL‐6)

  2014cites this paper
• Targeting interleukin-6 in inflammatory autoimmune diseases and cancers.

  2014cites this paper
• Proinflammatory cytokine interleukin-6 in prostate carcinogenesis.

  2014cites this paper
• Celastrol Blocks Interleukin-6 Gene Expression via Downregulation of NF-κB in Prostate Carcinoma Cells

  2014cites this paper
• Nuclear factor‐kappa B and interleukin‐6 related docetaxel resistance in castration‐resistant prostate cancer

  2013cites this paper
• Tumor and Stem Cell Biology JAK-STATBlockade Inhibits Tumor Initiation andClonogenic Recovery of Prostate Cancer Stem-like Cells

  2013cites this paper
• Inhibition of the IL-6/STAT3 signaling pathway for therapeutic intervention in prostate carcinogenesis and cancer cell differentiation

  2013cites this paper
• JAK-STAT blockade inhibits tumor initiation and clonogenic recovery of prostate cancer stem-like cells.

  2013cites this paper
• Platinum-resistance in ovarian cancer cells is mediated by IL-6 secretion via the increased expression of its target cIAP-2

  2012cites this paper
• Human prostate cancer cells induce inflammatory cytokine secretion by peripheral blood mononuclear cells.

  2012cites this paper
• Interleukin-6: A multifunctional targetable cytokine in human prostate cancer

  2012cites this paper
• Trial Watch: Monoclonal antibodies in cancer therapy

  2012cites this paper
• AUTHOR COPY ONLY Growth differentiation factor-15 upregulates interleukin-6 to promote tumorigenesis of prostate carcinoma PC-3 cells

  2012cites this paper
• Growth differentiation factor-15 upregulates interleukin-6 to promote tumorigenesis of prostate carcinoma PC-3 cells.

  2012cites this paper
• Inhibition of tumor growth and sensitization to chemotherapy by RNA interference targeting interleukin‐6 in the androgen‐independent human prostate cancer PC3 model

  2011cites this paper
• The anti‐interleukin‐6 antibody siltuximab down‐regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study

  2011cites this paper
• IL-6/IL-6R as a potential key signaling pathway in prostate cancer development.

  2011cites this paper
• Consistent interactions between tumor cell IL-6 and macrophage TNF-α enhance the growth of human prostate cancer cells in the bone of nude mouse.

  2011cites this paper
• TNF-blockade in patients with advanced hormone refractory prostate cancer

  2011cites this paper
• Cytokine disbalance in common human cancers.

  2011cites this paper
• Targeting Inflammatory Pathways in Epithelial Ovarian Cancer

  2011cites this paper
• IL-6 causes multiple effects in androgen-sensitive and -insensitive prostate cancer cell lines

  2011cites this paper
• IL-6/IL-6R as a potential key signaling pathway in prostate cancer development GUIDELINES CLINICAL PRACTICE World Journal of Clinical Oncology

  2011cites this paper
• Interleukin 6/interleukin 6 receptor interaction and its role as a therapeutic target for treatment of cachexia and cancer.

  2010cites this paper
• Effects of Siltuximab on the IL-6–Induced Signaling Pathway in Ovarian Cancer

  2010cites this paper
• Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells

  2010cites this paper
• Down-regulation of suppressor of cytokine signaling-3 causes prostate cancer cell death through activation of the extrinsic and intrinsic apoptosis pathways.

  2009cites this paper
• Expression of interleukin-6 is downregulated by 17-(allylamino)-17-demethoxygeldanamycin in human prostatic carcinoma cells

  2008cites this paper
• Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor.

  2008cites this paper
• Zoledronic acid effects interleukin-6 expression in hormone-independent prostate cancer cell lines.

  2008cites this paper
• Interleukin‐6 and its receptor in cancer

  2007cites this paper
• Sodium selenite inhibits interleukin-6-mediated androgen receptor activation in prostate cancer cells via upregulation of c-Jun.

  2007cites this paper
• The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1

  2007influential citation